Tampa, FL, May 26, 2008 --(PR.com
)-- Xcelience, a leader in early drug development services, was recently announced as a nominee and finalist for two highly coveted business awards. Its chief executive officer, Derek Hennecke, also received nominations for CEO of the year.
Xcelience’s growth and business practices are acknowledged by three of the world’s largest business research organizations: Ernst & Young; Tampa Business Journal, a division of the nation's largest publisher of metropolitan business newspapers; and the Greater Tampa Chamber of Commerce, an arm of the U.S. Chamber of Commerce.
Ernst & Young has named Xcelience’s president & CEO, Derek Hennecke, as a finalist for the “2008 Ernst & Young Florida Entrepreneur of the Year” awards. The nomination was based on Hennecke’s demonstration of extraordinary success in the areas of innovation, financial performance, his personal commitment to his community, and the company’s perpetual growth since its official formation in 2006. Xcelience would be named “The Best Emerging Company” for the entire state of Florida. Award recipients will be revealed at a ceremony to be held on Thursday, June 5, 2008 in Orlando.
Hennecke has also been recognized as a finalist for the “Ultimate CEO” awards by the Tampa Business Journal. This acknowledgment highlights CEOs and decision-makers in various categories. “This comes as quite a surprise but it just reflects that Xcelience is a great place to work and we enjoy the things that we are doing here,” said Hennecke. “We hire the most agile employees who can respond to our customers’ needs. Our pharmaceutical customers face a lot of pressure to get their drug candidates to the clinic and we are there for them. This recognition reflects the hard work of everyone.” Recipients will be announced on Thursday, May 29, 2008 during a ceremony at the Grand Hyatt in downtown Tampa.
In addition, Xcelience has been nominated for the Tampa Chamber of Commerce’s “28th annual Small Business of the Year Awards.” If it wins, Xcelience will be highlighted as one of the best companies in the Bay Area. “Having both our company and CEO honored in such a manner is indeed quite a privilege and honor. To be recognized in such a way, certainly establishes Xcelience as one of the top companies in both the state of Florida and the Tampa area,” expressed Randall Guthrie, Vice President. “We are certainly proud and glad to be part of Xcelience and the leadership provided by Derek Hennecke as we continue to grow our early drug development services company here in Tampa and provide ‘first–in-class’ services for the pharmaceutical industry worldwide.” Winners for this award will be announced on Friday, September 19, 2008 at an “Oscar-themed” event with over 1,000 scheduled attendees.
The Rise of an Empire
Originally the formulation division of MDS Pharma, Xcelience has been developing formulations for clients throughout the pharmaceutical industry since 1997. Xcelience was officially formed in spring 2006 when Hennecke was faced with a difficult choice of buying the company out from then corporate parent MDS Pharma. Its unique corporate structure allows project teams to work intensively with clients and bring an extension of their organization into the Xcelience lab. The company operates out of two 25,000 square foot facilities.
Xcelience is the premier source for unsurpassed quality in drug development services. The company brings together the industry's most experienced and talented scientists, consistently and efficiently moving compounds through the research and development continuum to regulatory approval.
The lab uses only state-of-the-art equipment, highlighted by the patented Xcelodose® which fills API directly to capsules (Xcelodose is a registered trademark of Capsugel BVBA). This and other technologies give Xcelience unparalleled speed to market without compromising its absolute commitment to quality.